Treatment of acute myeloid leukemia: State-of-the-art and future directions
- 1 July 2002
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 39 (3) , 4-10
- https://doi.org/10.1053/shem.2002.35977
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive MalignanciesJournal of Clinical Oncology, 2002
- Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory LeukemiaJournal of Clinical Oncology, 2002
- Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignanciesSeminars in Hematology, 2001
- Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the MicrotubulesJournal of Biological Chemistry, 2000
- The World Health Organization Classification of Neoplasms of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting – Airlie House, Virginia, November, 1997The Hematology Journal, 2000
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: A CALGB phase I studyAmerican Journal of Hematology, 1990